Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): Results of an open-label, 1-year study

BMC Nephrology

Volumn 10, Issue 1, 2009, Pages

  Frei, Ulrich ^a   Kwan, Jonathan Tc ^b   Spinowitz, Bruce S ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ST HELIER HOSPITAL   (United Kingdom)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE; FEMALE; HEADACHE; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOTENSION; INFECTION; INJECTION SITE PAIN; IRON DEFICIENCY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; PERITONEAL DIALYSIS; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRURITUS; SIDE EFFECT; SKIN ULCER; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; AGED; BLOOD; CHRONIC DISEASE; FOLLOW UP; KIDNEY DISEASE; MIDDLE AGED; PATIENT; RENAL REPLACEMENT THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CHRONIC DISEASE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY DISEASES; MALE; MIDDLE AGED; PATIENT DROPOUTS; PERITONEAL DIALYSIS; RENAL DIALYSIS; YOUNG ADULT;

EID: 63849340629     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-10-5     Document Type: Article

References (17)

1. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. CY Hsu CE McCulloch GC Curhan, J Am Soc Nephrol 2002 13 504 510 10.1097/01.ASN.0000034200.82278.DC 11805181
2. The prevalence of anemia in patients with chronic kidney disease. W McClellan SL Aronoff WK Bolton S Hood DL Lorber KL Tang TF Tse B Wasserman M Leiserowitz, Curr Med Res Opin 2004 20 1501 1510 10.1185/030079904X2763 15383200
3. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. A Besarab WK Bolton JK Browne JC Egrie AR Nissenson DM Okamoto SJ Schwab DA Goodkin, N Engl J Med 1998 339 584 590 10.1056/NEJM199808273390903 9718377
4. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990 300 573 578 2108751
5. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. DA Revicki RE Brown DH Feeny D Henry BP Teehan MR Rudnick RL Benz, Am J Kidney Dis 1995 25 548 554 10.1016/0272-6386(95)90122-1 7702049
6. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. F Locatelli P Aljama P Barany B Canaud F Carrera KU Eckardt WH Horl IC Macdougal A Macleod A Wiecek, Nephrol Dial Transplant 2004 19 Suppl 2 ii1 47 10.1093/ndt/gfh1032 15206425
7. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. R Deicher WH Horl, Drugs 2004 64 499 509 10.2165/00003495-200464050-00004 14977387
8. Erythropoietin produced by a human cell line has only trace levels of potentially immunogenic N-glycolylneuraminic acid residues. Z Shahrokh S Flatman M Davies A Baycroft M Heartlein, haematologica/the hematology journal 2006 91 Suppl 1 208
9. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. BS Spinowitz RD Pratt, Curr Med Res Opin 2006 22 2507 2513 10.1185/030079906X158048 17166333
10. Epoetin delta for the treatment of anemia in patients with CKD not requiring haemodialysis. RD Pratt, Poster presented at the American Society of Nephrology Renal Week 2006
11. Epoetin delta in the management of renal anaemia: results of a 6-month study. KJ Martin, Nephrol Dial Transplant 2007 22 3052 3054 10.1093/ndt/gfm490 17660186
12. The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease. KJ Martin, Clin Nephrol 2007 68 26 31 17703832
13. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. JT Kwan RD Pratt, Curr Med Res Opin 2007 23 307 311 10.1185/030079906X162755 17288685
14. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. WB Smith JA Dowell RD Pratt, Clin Ther 2007 29 1368 1380 10.1016/j.clinthera.2007. 07.014 17825688
15. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. LG Weiss N Clyne J Divino Fihlho C Frisenette-Fich J Kurkus B Svensson, Nephrol Dial Transplant 2000 15 2014 2019 10.1093/ndt/15.12.2014 11096148
16. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. F Locatelli CA Baldamus G Villa A Ganea AL Martin de Francisco, Am J Kidney Dis 2002 40 119 125 10.1053/ajkd.2002.33920 12087569
17. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999 14 Suppl 5 1 50 10513295